Pharmacist Intervention, Polypharmacy Patients
Conditions
Keywords
polypharmacy patients, pharmacist intervention, health-related quality of life
Brief summary
Brief summary: The randomised controlled trial investigates the effect of a pharmacist intervention targeting polypharmacy patient at two levels medical clinics and patient level. The purpose is to gain more knowledge to patients and physicians about their medication and to see changes in the patient's medication and health-related quality of life.
Detailed description
The main objective of the randomised controlled trial is to investigate the clinical effects of the roll-out of the systematic offer from Nord-KAP in the North Denmark Region at two different levels (medical clinic and patient-level). The primary outcome is changes in the participant's medicine from baseline to follow up and changes in healthcare usage Secondary outcomes include investigation of cost-effectiveness and changes in patients health-related quality of life. The hypothesis is that the regional intervention delivered by the pharmacists, from Nord-KAP, can lead to a decrease in medical products compared with a control group between baseline and at 6-month follow-up. * Will the use of a pharmacists intervention lead to a decrease in the number of polypharmacy patients in medical clinics compared to a control group of medical clinics? * Will the use of a pharmacist intervention lead to an increase in the polypharmacy patients health-related quality of life compared to a control group?
Interventions
OTHERSystematic pharmacist intervention
Already described in the arm group intervention group for patient level
Sponsors
The Quality Unit for General Practice North Denmark Region
Aalborg University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE (Subject, Caregiver)
Masking description
The medical clinics and polypharmacy patients are blinded from the randomisation process.
Intervention model description
RCT of The intervention and control groups will both have access to their physician as usual. At the medical clinic level the intervention group will receive the pharmacist intervention and other medical clinics will act as control groups. At patient level the intervention group will receive the pharmacist intervention and the control group are asked to evaluate the current treatment option.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with more than 5 medicinal products prescribed besides skin remedies and antibiotic * Above 18 years * Patients in continuous medication treatment
Exclusion criteria
* Terminal patients * Patients who are not motivated to comply with the instruction of the trial * Do not speak/or understand written Danish * Patients lacking legal capacity * Patients living at nursing homes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in polypharmacypatients medication | 6 months | The primary outcome at patient level is changes in the patients medication use at baseline and 6-month follow-up defined as the amount of medicine prescribed. Measuring the amount of medicine is extracted by the pharmacist from the participants SMC. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Health-related quality of life | 6 months | HRQoL as measures of effect for the economic evaluations. HRQoL is measured by the EQ-5D-5L questionnaire and converted into quality of life which is a scale from o to 1 where 0 correspondts to death and 1 indicates perfect health |
| Healthcare services | 6 months months and long term follow-up | Use of healthcare services to estimate costs for the economic evaluation. Use of health care services are measured by Danish health registers. |
| Amount of medicine pr patient in each medical clinic | 6 months | The primary outcome for the medical clinics are changes in the patients medication at baseline and at six months follow-up |
| Medical clinic number of polypharmacy patients | 6 months | . A count of the total number of polypharmacy patients in each medical clinic is conducted at baseline and six months follow-up |
Countries
Denmark
Contacts
Primary ContactJesper Søndergaard, MsC
Outcome results
None listed